Allegro NV, a biomedical company developing transformative nanotechnology-based treatments for degenerative joint disease, today presented positive preclinical data demonstrating the satisfactory ...

In an era of rising patient expectations and rapidly evolving healthcare standards, The Trust Hospital Company Ltd stands out ...

A team of nurses created a standardized patient handoff process that improved communications between nurses and with patients.

Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

When it comes to healthcare, finding the best hospital is critical. At Asian Hospital and Medical Center, which is among the ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...

The Phase 4 ENABLE study is set to be first in the U.S. to collect real-world safety and efficacy data of Briumvi for ...

Three state-funded residential treatment facilities serving children and teens with serious mental health challenges could ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announc ...

In influenza vaccination, PFSs may cost more per dose than multidose vials (MDVs), but could offer advantages in speed, disposal, wastage and patient safety owing to premeasured accurate doses ...

SmartfIRE 12-month data demonstrated 86.9% effectiveness when utilized with high adherence to the recommended ablation workflow and significant quality of life improvements using the Dual Energy ...